Creating a more agile timeline in biologics development

BioStreamline extended to work on next generation therapies

The BioStreamline project brings a unique approach to mitigating biotherapeutic development challenges using state of the art technologies to provide developers with a better understanding of candidate molecules earlier in the development process. This should allow developers to make better informed development decisions about which molecules to progress in development — reducing risk, cost and time.

BioStreamline (a 3 year project, total value of £11.2M) focussed on the supply chain for monoclonal antibodies. The project was made up of six partners from all sections of the drug development pipeline and supported by funding from the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI). The six partners included Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery, Alcyomics Ltd and CPI. By bringing together global companies from across different cutting-edge areas, the project gained complementary assets and expertise from each of the partners.


UCB Pharma
Sphere Fluidics
Finance Birmingham
Department for Business, Energy and Industrial Strategy



An input is a unique capability, service or method of support that was provided, such as equipment or expertise.

  • Provided open access to CPI’s state-of-the-art facilities 
  • Shared expert technical and industry knowledge 
  • Provided project management and business support services for publicly funded R&D projects 


An output is the result of the work, such as an experimental finding, an actual product or a pilot demonstrator.

  • Development of a new single cell analysis system (Cyto-Mine™)
  • New approaches to cell line development using CRISPR allowing rational inclusion of specific cell line features 
  • Developability data (biochemical, biophysical, stability) from a defined a panel of 50+ mAb (selected from a panel of 200+ mAb sequences) and generation of decisional tool 
  • Investigation of easy to implement, preclinical assessment of immunogenicity risks 


An outcome arises from implementing the outputs, for example, a profit, an investment, providing jobs or delivering societal benefits. Outcomes continue once an innovation has been implemented and deliver benefit every year.

  • Decisional tool to support molecule development assessment 
  • New products and approaches available for shortening cell line development 
  • Database of molecule information for developability assessment and further investigation by advanced data analytics 
  • Exemplification of collaborative project approach which would be applicable to other therapeutic modalities including viral vectors 

The challenge

CPI was involved from the conception of the project through planning, partner selection and delivery. The challenge being addressed is that the biopharmaceutical industry has badly needed a more efficient supply chain that enables it to make predictions about the problems associated with developing new biotherapeutics reducing the risk and cost of commercialisation.

How CPI helped

As well as managing the project CPI inputs involved use of their expertise and facilities to generate samples of the 50+ shortlisted panel of monoclonal antibodies, generation of biochemical, biophysical and stability data on the molecules as well as data analysis.




      Let's innovate together

      To discover how CPI can help your business, speak to one of our experts today.

      Contact Us
      CPI is your innovation partner to make your ideas a reality.